ProCE Banner Activity

Treatment Approach for ITP When Standard Second-line Therapy Fails: Novel and Emerging Therapies Under Development for ITP

Slideset Download
Download these slides from a live symposium to gain more insight into novel and emerging therapies under development for ITP

Released: August 19, 2022

Expiration: August 18, 2023

Share

Faculty

David J. Kuter

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Dova Pharmaceuticals

Novartis Pharmaceuticals Corporation

Sanofi Genzyme

Faculty Disclosure

Primary Author

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

David J. Kuter, MD, DPhil: consultant/advisor/speaker: Actelion, Agios, Alnylam, Amgen, Argenx, BioCryst, Bristol-Myers Squibb, Caremark, CRICO, Daiichi Sankyo, Dova, Genzyme, Immunovant, Incyte, Kyowa-Kirin, Merck Sharp Dohme, Momenta, Novartis, Pfizer, Principis, Protalex, Protalix, Rigel, Sanofi Genzyme, Shionogi, Shire, Takeda, UCB, Zafgen; researcher: Actelion, Agios, Alnylam, Amgen, Argenx, Bristol-Myers Squibb, Immunovant, Kezar, Principia, Protalix, Rigel, Takeda, UCB.